A comparative approach of tumor associated inflammation in mammary cancer between humans and dogs by Carvalho, Maria et al.
Review Article
A Comparative Approach of Tumor-Associated Inflammation in
Mammary Cancer between Humans and Dogs
Maria Isabel Carvalho,1,2 Ricardo Silva-Carvalho,3 Isabel Pires,1,2 Justina Prada,1,2
Rodolfo Bianchini,4 Erika Jensen-Jarolim,4,5 and Felisbina L. Queiroga2,6,7
1CECAV, University of Tra´s-os-Montes and Alto Douro, 5001-801 Vila Real, Portugal
2Department of Veterinary Sciences, University of Tra´s-os-Montes and Alto Douro, 5001-801 Vila Real, Portugal
3Centre of Biological Engineering (CEB), University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal
4The Interuniversity Messerli Research Institute, The University of Veterinary Medicine Vienna,
Medical University Vienna and University Vienna, Vienna, Austria
5Institute of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology,
Medical University Vienna, Vienna, Austria
6Center for the Study of Animal Sciences, CECA-ICETA, University of Porto, 4051-401 Porto, Portugal
7Center for Research and Technology of Agro-Environment and Biological Sciences (CITAB),
University of Tra´s-os-Montes and Alto Douro, 5001-801 Vila Real, Portugal
Correspondence should be addressed to Felisbina L. Queiroga; fqueirog@utad.pt
Received 26 July 2016; Revised 24 October 2016; Accepted 3 November 2016
Academic Editor: Stephen H. Safe
Copyright © 2016 Maria Isabel Carvalho et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Infiltrating cells of the immune system are widely accepted to be generic constituents of tumor microenvironment. It has been
well established that the development of mammary cancer, both in humans and in dogs, is associated with alterations in numbers
and functions of immune cells at the sites of tumor progression. These tumor infiltrating immune cells seem to exhibit exclusive
phenotypic and functional characteristics and mammary cancer cells can take advantage of signaling molecules released by them.
Cancer related inflammation has an important role in mammary carcinogenesis, contributing to the acquisition of core hallmark
capabilities that allow cancer cells to survive, proliferate, and disseminate. Indeed, recent studies in human breast cancer and in
canine mammary tumors have identified a growing list of signaling molecules released by inflammatory cells that serve as effectors
of their tumor-promoting actions.These include the COX-2, the tumor EGF, the angiogenic VEGF, other proangiogenic factors, and
a large variety of chemokines and cytokines that amplify the inflammatory state. This review describes the intertwined signaling
pathways shared by T-lymphocytic/macrophage infiltrates and important tissue biomarkers in both human and dog mammary
carcinogenesis.
1. General Introduction
Most of the knowledge on tumor biology is derived from
human and rodent studies. However, systematic comparison
to spontaneous tumors in canine cancer patients could not
only contribute to the improved understanding of the disease
but contribute also to “translating clinical trials from human
to veterinary oncology and back” [1]. This review aimed to
compare, in both species, the relevant findings on the role of
the immune regulation in mammary cancer.
Tumors are recognized as organs with high complexity
and infiltrating immune cells are increasingly accepted to be
generic constituents of them [2, 3]. Solid cancers often show
signs of inflammation and are infiltrated by many leukocyte
populations including T-lymphocytes and macrophages [4,
5]. The role of inflammation in carcinogenesis is not new.
Over a century ago, a causal relationship between chronic
inflammation and cancer formation was proposed taking
into consideration the observations that cancers frequently
develop at sites of chronic inflammation [6–8].
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Figure 1: Cancer related inflammation has an important role in mammary carcinogenesis, contributing to tumor evasion of immune
surveillance, matrix remodeling and angiogenic switch, acquisition of metastatic capacity, and tumor proliferation and progression.
Chronic inflammatory responses associated with tumor
sites have a multifaceted role in carcinogenesis. Indeed,
the chronic inflammation contributes to the acquisition
of different hallmark capabilities by incipient neoplasms.
Inflammatory cells can induce genomic instability, alterations
in epigenetic events, and consequent inappropriate gene
expression [9, 10]. Furthermore, immune cells can provide
bioactive molecules to the tumor microenvironment, includ-
ing (i) growth factors that sustain proliferative signaling; (ii)
survival factors that limit cell death; (iii) proangiogenic fac-
tors and extracellular matrix-modifying enzymes facilitating
angiogenesis, invasion, and metastasis; and (iv) inductive
signals that lead to activation of other hallmark-facilitating
programs [10–13].
During tumor progression, changes in tumor microen-
vironment induce a switch in innate immune cells toward a
protumorigenic function and actively contribute to immune
tolerance, preventing rejection of the tumor by the immune
system [2, 14]. In this process, dendritic cells (DCs)
maturation can be suppressed by changes in the cytokine
balance (increased VEGF, TGF𝛽, IL-10, IL-6, and COX-2 and
reduced IL-4, IL-12, IFN-𝛼, and IFN-𝛾) within the tumor,
which significantly impairs the antigen presenting function
of these cells [8].
Mammary cancer remains a major clinical challenge with
considerable mortality both in humans and in dogs [15–18].
Over the years, research on the association between inflam-
mation and mammary cancer pathogenesis has blossomed
in both species [19–22]. Alterations of the inflammatory
components within the tumor microenvironment have a
significant role during carcinogenesis and recent studies have
highlighted the importance of tumor-associated immune
cells and their influence on neoplastic progression [17, 23–
26].
This review summarizes the intertwined signaling path-
ways shared by T-lymphocytic/macrophage infiltrates and
important tissue biomarkers in both human and dog mam-
mary carcinogenesis (all the contents are synthetized in
Table 1 and illustrated in Figure 1). The inflammatory
responses in mammary cancer sites are able to orchestrate
hallmark-facilitating programs in the tumor microenviron-
ment [27].These phenomena could be important for progno-
sis as well as for the development of therapies aimed at redi-
recting the immune cell actions toward tumor destruction.
2. Inflammatory Cells and
Sustained Angiogenesis
Similar to normal tissues, vasculature has an important role in
tumor growth and progression since it provides the necessary
oxygen and nutrients that are present in the blood and allows
discarding the toxic waste-products of metabolism [28, 29].
The tumor vasculature, driven by angiogenesis, is thus crucial
for growth and survival of tumor cells, but it may also be
exploited as a target for cancer therapy [30, 31].
The association between angiogenesis and mammary
tumors has been a common subject of interest in humans
and dogs [32–34]. In fact, human breast cancer progression
is associated with robust angiogenic activity [35]. In highly
metastatic human breast cancer there is an upregulation in
the expression of proangiogenic factors, such as VEGF [36].
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Table 1: Relationship between T-lymphocytic and macrophages infiltrate and tissue biomarkers in human and dog mammary tumors.
Tissue biomarkers T-lymphocytic and macrophages infiltrate
Human breast cancer Canine mammary tumors
Angiogenesis
(i) T-cells can secret VEGF [39]
(ii) Treg cells release TGF𝛽1 and induce VEGF expression
[40]
(iii) M2 macrophages are responsible for the production of
VEGF, uPA, MMP9, and CCL18 promoting tumor
neovascularization [48, 51]
(i) Positive correlation between CD3+
T-cells, VEGF, and microvessel density [52]
(ii) M2 macrophages infiltration is
associated with VEGF expression [56]
Invasion and
metastasis
(i) IL-10 produced byTh2-polarized CD4+ T-lymphocytes
promotes M2-TAMs polarization, enhancing metastasis
through EGFR signaling activation [60]
(ii) IL-1𝛽 elicits IL-17 expression from T-cells, resulting in
expansion and polarization of neutrophils that have the
ability to suppress cytotoxic CD8+ T-lymphocytes and
favors metastatic spread [61]
(iii) MMP-2, MMP-9, and CCL18 produced by
macrophages increase tumor cells motility and
invasiveness [62, 63]
(i) CD4+ T-cells count and TAMs density
are higher in metastatic CMT; CD8+ T-cells
count is higher in tumors without metastatic
behavior [64–66]
COX-2
(i) COX-2-derived PGE2 enhances the production of IL-4,
IL-5, and IL-10 byTh2 cells and inhibits the antitumorTh1
cytokines (IFN-𝛾 and IL-2) [67, 68]
(ii) PGE2 inhibits CD8+ T-cells proliferation and
antitumor activities [69]
(iii) COX-2/PGE2 pathways increase tumor Treg cells
infiltration, differentiation, and function [70] and can
change the tumor-associated macrophages phenotype
fromM1 to M2 [71, 72]
(i) Tumors with high COX-2/CD3 and high
COX-2/MAC are associated with tumor
aggressiveness and shorter OS [73]
Receptor tyrosine
kinases
(i) T-lymphocytes and TAMs produce EGFR ligands being
involved in tumor progression [74–76]
(ii) FoxP3+ Treg cells express EGFR under inflammatory
conditions, which is related to tumor cells invasion and
metastasis [77]
(iii) c-kit dependent signaling supports an immune
twisting towardTh2 andTh17 subsets and the cytokines
produced induce T-cell tolerance, contributing to cancer
development [78–80]
(iv) c-kit inhibitors induce a reduction of TAMs and Treg
cell numbers and contribute to the enhancement of Th1
and CD8+ T-cells [81–84]
(i) Concurrent COX-2/EGFR expression is
associated with higher numbers of tumoral
CD3+ T-lymphocytes and characteristics of
tumor aggressiveness [19]
(ii) High CD3/c-kit tumors are associated
with variables of tumor aggressiveness and
shorter overall survival of animals [52]
Similarly, in veterinary medicine, the presence of proliferat-
ing endothelial cells and blood vessels in intratumoral and
peritumoral regions of benign and malignant canine mam-
mary tumorswas shown, with the peritumoral regions having
the largest blood vessel area and perimeter. Furthermore,
malignant tumors have significantly more new vessels and
proliferating endothelial cells compared with benign tumors
and normal mammary gland tissues [32]. We have shown
previously that high microvessel density in canine mammary
cancer was significantly correlated with tubule formation,
with the histological grade of malignancy and with clinical
stage [37].
Infiltrating immune/inflammatory cells secrete a diverse
repertoire of proinflammatory mediators, such as cytokines,
chemokines, growth factors, and prostaglandins, which trig-
ger the influx of even more inflammatory immune cells to
the tumor microenvironment. Furthermore, some of these
proinflammatory mediators directly stimulate the migra-
tion and proliferation of endothelial cells, thus promoting
angiogenesis and consequently tumor growth [10, 38]. T-
cells have an important role in the initiation and progression
of inflammation by secreting a large number of cytokines
and chemokines [39]. It was shown in in vitro studies
that T-cells in inflammatory sites are in intimate contact
with endothelial cells and influence angiogenesis. In fact, T-
cells can secrete VEGF by specific antigens stimulation or
by IL-2 and by hypoxia [39]. The human invasive breast
carcinoma had a higher FoxP3 expression compared to the
ductal carcinoma in situ and the adjacent normal tissues.
Intratumoral levels of FoxP3, TGF𝛽1, and VEGF were found
to be positively correlated to each other [40]. TGF𝛽1, by T-
cell receptor (TCR) stimulation, induces FoxP3 expression
in naive CD4+CD25−FoxP3− T-cells and converts them into
FoxP3+ regulatory T-cells. Furthermore, Treg cells enhance
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the TGF𝛽1 effects thereby creating a positive autoregula-
tory loop of TGF𝛽1 signaling in CD4+CD25− T-cells that
potentially stabilizes their regulatory phenotype [41, 42]. The
TGF𝛽1 and FoxP3 shared pathways induce an upregulated
expression of VEGF which increases cancer vascularity and
progression [40]. DCs are immunomodulatory cells that
initiate adaptive immune responses and exert proangiogenic
effects in the tumor microenvironment. Immature DCs pro-
mote angiogenesis and tumor growth, whereas mature DCs
are known to suppress angiogenesis. Using a mouse model
of human breast carcinoma it was observed that rapid tumor
growth is associated with the infiltration of immature DCs
[43]. Tumor-derived VEGF-A is the main angiogenic factor
that prevents DCs maturation by inhibiting the activation
of the NF-𝜅B via VEGFR-1 signaling [44]. Furthermore,
another study reported that in human breast cancer DCs are
differentiated into a phenotype that induces the expansion
of Tregs by the expression of IL-10 and TGF𝛽1 [45], and
the latter is a factor that indirectly induces the expression
of VEGF [40]. Monocytes which become tumor-associated
macrophages (TAMs) when entering the tumor also act as
proangiogenic factor in human breast cancer [46]. In fact, the
tumor microenvironment polarizes macrophages toward the
M2 phenotype, which is characterized by elevated expression
of potent proangiogenic factors. A transgenic mouse suscep-
tible to mammary cancer confirmed that both the angiogenic
switch and the progression to malignancy are regulated by
infiltrated macrophages in the primary mammary tumors
[47]. TAMs are thus responsible for the production of VEGF,
of urokinase-type plasminogen activator (uPA), and ofmatrix
metalloproteinase-9 (MMP-9) in human breast carcinomas
[46, 48]. Additionally, some studies in human breast cancer
showed that the number of macrophages present in tumor
sites directly correlates with increased microvessel density,
tumor size, and cell proliferation [49, 50]. Specifically, the
infiltration of TAMs that express the chemokine CCL18
was positively associated with microvessel density in breast
cancer. In fact, the synergistic expression of CCL18 and
VEGF by the TAMs promoted endothelial cell migration and
angiogenesis in this type of cancer [51].
Some studies from veterinary oncology report that in
canine mammary tumors proinflammatory mediators pro-
duced by the tumor-infiltrated inflammatory cells correlate
with progression and angiogenesis [20, 52–54]. In accor-
dance, we show in dog mammary tumors a positive associa-
tion between infiltrating CD3+ T-cells, VEGF, and microves-
sel density, implying that CD3+ T-lymphocyte cytokines in
this type of cancer may stimulate angiogenesis through the
induction of the proangiogenic VEGF. Additionally, this high
CD3/VEGF expression was associated with an elevated grade
of malignancy, presence of neoplastic intravascular emboli,
presence of lymph node metastasis, and poor prognosis
[52]. It was further shown that myeloid-derived suppressor
cells (MDSCs) were significantly increased in stages III and
IV dog mammary tumors and in this case MDSCs had
significantly alteredmolecular pathways expressing amplified
activation of IL-28/IL-28RA (IFN-𝛾) signaling.Moreover, IL-
28 secreted by the MDSCs stimulates the STAT3 pathway
which increases VEGF-C expression and therefore induces
angiogenesis [55]. A positive correlation betweenmicrovessel
density and mast cells in malignant canine mammary cancer
was found, which, in turn, suggests that these immune
cells play an important role in canine mammary cancer
angiogenesis, similar to human breast cancer [53]. TAMs in
caninemammary cancer have already been associated, by our
group, with skin ulceration, histological type, nuclear grade,
tubular differentiation, and decrease in overall survival [56].
Similarly to human breast cancer, in caninemammary cancer
themacrophages also polarize toward theM2phenotype [57].
Recently, we and others demonstrated that TAM infiltration
is significantly associatedwithVEGF expression inmalignant
canine mammary tumors and that genes involved in angio-
genic cellular pathways have been significantly upregulated
inmacrophages cocultured with caninemammary tumor cell
lines [20, 58].
3. Inflammatory Cells, Tissue Invasion,
and Metastasis
Cancer, in its most aggressive form, is a disease character-
ized not only by uncontrolled cell proliferation and growth
but also by uncontrolled cell migration. The activation of
angiogenic vasculature is very important for cells to amplify
locally (i.e., malignant transformation) and/or spread sys-
temically (i.e., metastasize) [59]. Cancer metastasis involves
a complex sequence of processes starting with local invasion,
followed by entry of the cancer cells into blood or lymphatic
vessels, extravasation in distant tissues, and formation of
micrometastasis, followed then by progression into macro-
scopic tumors [29].
The cross talk between cancer cells and other cells present
in the tumor microenvironment is decisive for invasive
growth andmetastasis. In fact, tumor invasion andmetastasis
can be potentiated by an inflammatory infiltrate in tumor
sites [85]. In addition to promoting angiogenesis, inflamma-
tory infiltrates promote metastatic dissemination by enhanc-
ing migratory/invasive potential of neoplastic cells through
the production of tissue remodeling proteases, cytokines, and
growth factors [86, 87]. Human breast cancer development
is characterized by a significant increase in lymphocytes
in the neoplastic stroma [60]. For instance, Th2-polarized
CD4+ T-lymphocytes that express IL-4 promote invasion
and subsequentmetastasis of mammary adenocarcinomas by
regulating the polarization and effector function of TAMs.
In turn, M2-TAMs enhance metastasis through activation
of EGFR signaling in human malignant mammary epithelial
cells [60]. In mice bearing mammary tumors it was demon-
strated that IL-1𝛽 elicits IL-17 expression by gamma delta T-
cells, resulting in expansion and polarization of neutrophils
by granulocyte colony-stimulating factor (G-CSF) action.
Tumor-induced neutrophils acquire the ability to suppress
cytotoxic CD8+ T-lymphocytes, which favors the metastatic
spread [61].
Hence, even the recruitment of monocytes to the tumor
has an important role. In fact, CCL2 synthesized bymetastatic
tumor cells is critical for recruitment of a subpopulation of
CCR2 expressing monocytes that enhance the subsequent
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cell survival and extravasation through VEGF and M-CSF
production [88].
Multiple studies in human cancers, including breast
cancer, have reported that the presence of TAMs correlates
with aggressive disease and outcome [89]. Structural changes
in the extracellular matrix are necessary for cell migration.
The proteolytic activities of MMP-2 and MMP-9, expressed
by macrophages, promote the release of cryptic fragments by
cleaving laminin-5 𝛾2 chains which mimic EGF ligand and
induce cell motility and invasion in EGFR overexpressing
human breast carcinoma cell lines [46, 62]. The coculture
with M1 and M2 macrophages increased migration of ER-
positive breast cancer cell lines [90]. In a study using a mouse
model for breast cancer it was demonstrated that CSF1 may
promote metastatic potential by regulating the infiltration
and function of TAMs [91]. In fact, using a metastatic
breast cancer model it was possible to comprehend that the
paracrine loop signaling between TAMs, which supply EGF,
and breast cancer cells, which on the other hand supply CSF1,
is sufficient for the promotion of invasion and migration
[92, 93]. CCL18 released by breast TAMs promoted the
invasiveness of cancer cells by triggering integrin clustering
and enhancing their adherence to the extracellular matrix
[63]. Another study showed that macrophage migration
inhibitory factor (MIF) also promoted tumor metastasis by
increasing the prevalence of a highly immunosuppressive
subpopulation of MDSCs within the tumor [94].
There are few studies in canine mammary cancer
regarding the influence of immune cells in tumor invasion
and metastasis [55, 64, 95]. The role of lymphocytes and
macrophages in canine mammary tumor metastasis is not
fully understood. When a high number of CD8+ T-cells were
found inmetastatic caninemammary cancer the authors sug-
gested the involvement of this lymphocyte subtype in tumor
metastasis [96]. Contrary to this study, another group showed
that the relative percentage of CD4+ T-cells was higher
in canine mammary tumors that metastasized, whereas
CD8+ T-cells percentage was higher in tumors that did not
metastasize [65, 66]. In terms of TAMs, their density was
significantly higher in canine mammary adenocarcinomas
that metastasized [64]. Furthermore, a microarray analysis to
determine the global gene expression of a coculture of canine
macrophages and canine mammary cancer cells showed an
upregulation of genes involved in angiogenesis in TAMs
and an increase in the migratory and invasive capabilities
of cancer cells [95]. Mucha et al. showed, for the first
time, that MDSCs demonstrated increased activation of IL-
28/IL-28RA (IFN-𝛾) signaling, which stimulates STAT3 in
canine mammary tumor cells therefore promoting epithelial-
mesenchymal transition (EMT) and increased invasion and
migration [55].
4. Inflammatory Cells and Cancer
Cell Biomarkers
4.1. Inflammatory Infiltrates and Tumor COX-2 Expression.
Cyclooxygenase (COX) is the enzyme responsible for the
biosynthesis of various prostanoids (lipidmediators that have
several biological functions) by the conversion of arachidonic
acid released from the phospholipid membrane through the
action of cytosolic phospholipase A2 [97].
Human and laboratory animal studies report COX-
2 upregulation in mammary cancer [98–101] and several
lines of evidence now strongly support that this enzyme,
during mammary tumorigenesis, mediates tumor survival by
several mechanisms: (i) inhibiting the tumor cell apoptosis
and inducing tumor cell proliferation; (ii) increasing tumor
progression by altering cells morphology; (iii) increasing cell
motility and migration; (iv) sustaining proliferative signal-
ing; (v) inducing the production of metastasis-promoting
MMPs; and (vi) stimulating the tumor angiogenic switch
[102, 103].
TheCOX-2-derived products, mostly prostaglandin (PG)
E2 (thought to be the main tumorigenic COX-2-derived
product), are known to act not only in classical cancer
signaling pathways to promote carcinogenesis in primary
tumor cells but also in the tumor microenvironment which
contains multiple resident and infiltrating cells (including
immune cells) as well as the growth factors and cytokines
released by them [29, 67]. Recent findings revealed that COX-
2-produced prostaglandins are potent lipidmolecules that act
as immunomodulators in key aspects of mammary tumor
immunity [68, 104–106].
In human breast cancer COX-2-derived PGE2 has the
ability to influence local immune responses in the tumor
stroma contributing to tumor evasion of immune surveil-
lance and supporting tumor development and metastasis
[102, 106]. PGE2 has diverse effects on the regulation and
activity of T-cells [106, 107]. Recently, PGE2 has been
implicated in the enhancement of protumorigenic Th2-type
cytokine, such as IL-4, IL-5, and IL-10, and inhibition of
the anti-tumor Th1 cytokine production, such as IFN-𝛾 and
IL-2 [67, 68]. Receptors EP1–4, associated with different
intracellular signaling pathways, are responsible for medi-
ating the cellular effects of PGE2 [70]. The inhibition of
the Th1 cell proliferation is dependent on EP2 [108]. The
EP2 and perhaps the EP4 receptors mediate the suppressive
effects of PGE2 on T-cells [109]. The induction of the Th2
response by PGE2 ismodulatedmost probably by the second-
messenger cyclic adenosine monophosphate (cAMP), since
the biological products that increase the level of cAMPmimic
the effects of PGE2 [110, 111].
Even though there is limited knowledge regarding the
effects of PGE2 on CD8+ cytotoxic T-cells, it has been
shown that, as for Th1 cells, PGE2 can inhibit CD8+ T-cell
proliferation, suppress cytotoxic CD8+ T-cell actions against
the tumor, and, in terms of regulating cytokine production,
decrease the production of IFN-𝛾 by CD8+ T-cell clones
through a cAMP-dependent pathway [69]. Additionally, the
PGE2 effects during the priming of DCs with tumor antigens
inhibit completely the DCs ability to produce IL-12 and
prompt the production of high levels of IL-10 [112]. In this
process the PGE2-primed DCs induce the direct differenti-
ation of naive T-cells into Th2 cells, which further supports
the role of COX-2-derived PGE2 in biasing the immune
system toward Th2 and away from potentially beneficial Th1
responses in tumor sites [112, 113].
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COX-2 has some effects on FoxP3 expression and Treg
cell functions. Several studies have demonstrated that Treg
cells contribute to immunosuppression in cancer and inhibit
effector T-cells in a COX-2-dependent manner in mouse
models or in human peripheral blood [114–117]. An intra-
tumoral increase in COX-2 and PGE2 levels is strongly
correlatedwith the upregulation of FoxP3 and the suppressive
capabilities of Tregs in several human cancers [118, 119]. In
human breast cancer, COX-2-derived PGE2, acting through
EP2 and EP4, increases Treg infiltration, differentiation, and
function, which in turn suppress the maturation of other T-
cells leading to immunosuppression and increased tumor cell
survival [70].
Evidences from clinical and experimental studies indicate
that macrophages are versatile cells that are capable of
displaying different functional activities in order to promote
breast cancer progression andmetastasis [20, 120, 121]. TAMs
polarization in mammary tumor sites are modulated by
the tumor microenvironment and these cells are “educated”
adopting a role that facilitates angiogenesis, matrix break-
down, and tumor cellmotility in aCOX-2-dependentmanner
[71, 105].
A substantial body of work indicates the immune
suppressive role of COX-2 and describes the COX-
2/PGE2 modulation of macrophages, including the
downregulation of M1 macrophage markers/cytokines,
which elicit Th1 immune responses, and the upregulation
of M2 macrophage markers/cytokines, which block Th1
immune responses [71, 72]. Moreover, in the murine breast
cancer model, the selective COX-2 inhibitors can change the
tumor-associated macrophage phenotype from M2 to M1
[105].
Considering COX-2/PGE2-mediated immunomodula-
tion in human breast cancer, it is worth noting that the
immunosuppressive cell subtypes, modulated by COX-2
pathways, share common cytokine mediators and, more
importantly, each cell subtype can also generate PGE2provid-
ing an autocrine mechanism for prolonging and enhancing
their own immunosuppressive phenotype [122].This empha-
sizes the importance of exploring the tumor microenviron-
ment as a whole, rather than focusing on alterations in an
individual subset of tumor-associated cells [29]. Collectively,
these findings show that COX-2 and immune cells share
common signaling pathways in mammary carcinogenesis,
which are associatedwith changes in immune cell profiles and
functionality and the role ofCOX-2may allowneoplastic cells
to evade attack by the immune system.
In canine mammary tumors there are only a limited
number of studies focusing on the cross talk between COX-2,
cancer cells, and immune cells [19, 73] and this topic is incom-
pletely understood. Our team demonstrated a significant
association of high COX-2 immunoexpression with CD3+ T-
lymphocytes [19] and MAC387 macrophages [73]. Tumors
with concurrent high COX-2/CD3 and high COX-2/MAC
were statistically associated with variables of tumor aggres-
siveness (high histological grade of malignancy, presence
of neoplastic intravascular emboli, and presence of lymph
node metastasis) and shorter overall survival of animals [73].
These findings suggest that, similarly to human breast cancer,
T-lymphocytes, macrophages, and COX-2 share functions in
canine mammary carcinogenesis.
4.2. Inflammatory Infiltrates and Receptor Tyrosine Kinases
(RTKs). Receptor tyrosine kinases (RTKs) are cellular pro-
teins that have been intensively studied [52, 74, 75, 123].Their
role in the control of cellular growth and differentiation is
central to all organisms and has been found to participate in
human and animal neoplastic diseases [124–126].
There are several mechanisms by which tyrosine kinases
might acquire transforming functions. RTKs are essential
components of cellular signaling pathways that are active
during embryonic development and adult homeostasis [127].
Due to their roles as growth factor receptors, many RTKs
have been implicated in the onset or progression of various
cancers, including mammary cancer, either through recep-
tor gain-of function mutations in the corresponding genes
or through receptor/ligand overexpression by autocrine-
paracrine growth factor loops [128, 129].
The RTKs family include the human epidermal growth
factor receptor (EGFR) family with its members HER-
1/EGFR and HER-2, HER-3, and HER-4; platelet-derived
growth factor receptors (PDGFR, which include c-kit);
fibroblast growth factor receptors (FGFRs); VEGF; hepato-
cyte growth factor/scatter factor receptor (HGF/SFR); ephrin
receptors (Ephs); and the insulin receptor [128, 130, 131].
Here, we will only focus on the most important RTKs
in mammary carcinogenesis, the EGFR and c-kit which are
often overexpressed or mutated in this type of tumor [52, 126,
132, 133], since VEGF is already described above.
In human breast cancer, RTK signaling has been
described as being implicated in differentiation and migra-
tion of immune cells into tumor sites contributing to the
immune balance from activation to tolerance which is impli-
cated in tumor progression [75, 78, 134, 135]. Consequently, a
number of tyrosine kinase inhibitors (TKIs) have been devel-
oped which, besides direct anticancer effects, also increase
the number and function of effector immune elements, while
decreasing the amount and function of suppressor immune
cells [81, 136].
Studies in preclinical breast cancer mouse models
demonstrated that trastuzumab (monoclonal antibody
against HER2) and cetuximab (monoclonal antibody to
EGFR/HER-1) both have an important role in tumoral innate
and adaptive immunity, inducing natural killer (NK) cells
and cytotoxic as well asTh1 T-lymphocytes activity [137–140].
The great homology in the EGFR family among humans
and dogs [126] prompted us recently to produce a recombi-
nant canine anti-EGFR antibody for caninemammary tumor
treatment [125].
Several lines of evidence suggest that ligands to EGFR
family molecules (except HER-2) can be produced by non-
tumor cell types. The infiltrating T-lymphocytes in human
breast cancer can produce EGF [76] and analysis of breast
tumor explants revealed that EGF is also produced by TAMs
[74, 75, 141]. In fact, the important role of macrophage-
secreted EGFR ligands in malignant mammary tumor
progression leads to increased carcinoma cell invasion and
metastasis [75].
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Interestingly, one study showed that even FoxP3+ Treg
cells express EGFR under inflammatory conditions. The
stimulation with the EGF-like growth factor amphiregulin
markedly contributes to the enhancement of Treg cell func-
tions in vitro and in a tumor vaccination model [77].
In canine mammary cancer there is only one study
suggesting that concurrent COX-2/EGFR positive immu-
noexpression is associated with higher number of intratu-
moral CD3+ T-lymphocytes. In this work, tumoral CD3+ T-
lymphocytes may be influenced by inappropriate expression
of COX-2/EGFR. COX-2 overregulation and the resulting
increase in PGE2 levels induced overexpression of EGFR
pathways and may represent a strategy adopted by tumors
that contributes to the evasion of tumor-specific immune
response [19].
In several human tumors, including breast cancer, the
stem cell factor (SCF) that triggers the c-kit signaling path-
ways has been described as possibly being involved in the
complex relationship between immune cells and tumor cells
in the tumor microenvironment [78, 134]. c-kit upregulation,
on DCs, induces the activation of several signaling pathways
that block IL-12 and promote IL-6 production. c-kit depen-
dent signaling supports an immune twisting towardTh2 and
Th17 subsets and away from Th1 responses. The cytokines
produced induce T-cell tolerance and contribute to cancer
development [78–80].
Sunitinib and sorafenib,multikinase inhibitors that block,
among others, the VEGF and c-kit receptors [81], have the
ability to modify the mammary tumor microenvironment
in multiple ways, including the alteration of immune cell
infiltration by immune subset conditioning [142].These TKIs
may contribute to the enhancement of Th1 and CD8+ T-
cells intratumoral infiltration with cytolytic activity against
the tumor [81, 82]. Sunitinib could also block the conversion
of conventional CD4+FoxP3− T-cells into CD4+FoxP3+ Treg
cells [81]. Studies in vitro and using tumor-bearing mice
showed that c-kit inhibitors may induce a reduction of
Treg cell number, decreasing consequently the expression
of immunosuppressive cytokines (IL-10, TGF𝛽) [83]. Fur-
thermore, in mice, sunitinib prompted antiangiogenic effects
and promoted direct proapoptotic properties, resulting in a
decline of mammary tumor progression. Regarding TAMs,
their density was slightly reduced under sunitinib treatment
[84].
Caninemammary tumor studies on the interplay between
c-kit and tumor immunology are scarce. However, one
study demonstrated a positive correlation between CD3+
T-lymphocytes and c-kit immunoexpression. Tumors with
high CD3/c-kit were associated with tumor aggressiveness
(high histological grade ofmalignancy, presence of neoplastic
intravascular emboli, and presence of lymph node metas-
tases) and shorter overall survival of animals. The results of
this work are a first attempt to explore the possible common
signaling pathways between c-kit and immune system in
canine mammary carcinogenesis [52].
Therefore, the findings described above prove that RTK
pathways not only are important for the remodeling of
mammary tumor microenvironment but also could be a very
important target for tumor immunological therapy [135].
5. Concluding Remarks
Cancer can take advantage of the stromal inflammation [143].
T-lymphocytes, macrophages, and other inflammatory cells
in human and the dog mammary tumor microenvironment
acquired protumorigenic properties that are crucial to fuel
the major biological processes involved in tumor develop-
ment, progression, and metastasis [14, 46, 143, 144].
The involvement of inflammatory cells in tumor hallmark
acquisitions by supplying proangiogenic growth factors,
cytokines, and proteases and the recent success of checkpoint
inhibitors in clinical oncology approve the great relevance of
the dark side of immune regulation for driving cancer.
The similarities described above between humans and
dogs prove the value of dog as an important translational
model for comparative oncology in the study of themolecular
signaling based on tumor immunosuppression. In the future
continuing research on this topic seems to be relevant in
order to find novel immunotherapies that may target tumor
microenvironment interconnected pathways.
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